Cost minimization analysis of mainstay treatments in cutaneous lupus erythematous

Rizvi, Syed K.; Chong, Benjamin F.

doi:10.1111/dth.15190

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The only FDA‐approved indication for low‐dose MTX in pediatric patients is for polyarticular juvenile idiopathic arthritis (JIA) 10 . Nevertheless, low‐dose MTX is widely used off‐label for multiple inflammatory and autoimmune conditions in pediatric patients because of its efficacy, tolerability, 11–13 and accessibility 14,15 . These include morphea, psoriasis, atopic dermatitis, and alopecia areata, 16–39 among other conditions, as well as for prevention or reduction of neutralizing antibodies associated with biologic drug treatment 40,41 .…”

Section: Introductionmentioning

confidence: 99%

Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines

Siegfried

Arkin

Chiu

et al. 2023

Pediatric Dermatology

View full text Add to dashboard Cite

Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide variety of indications since then. However, despite widespread off‐label use, FDA labeling does not include approved indications for the use of MTX for many inflammatory skin diseases in pediatric patients, including morphea, psoriasis, atopic dermatitis, and alopecia areata, among others. Without published treatment guidelines, some clinicians may be hesitant to use MTX off‐label, or uncomfortable prescribing MTX in this population. To address this unmet need, an expert consensus committee was convened to develop evidence‐ and consensus‐based guidelines for use of MTX to treat pediatric inflammatory skin disease. Clinicians with experience and expertise in clinical research, drug development, and treating inflammatory skin disease in pediatric patients with MTX were recruited. Five committees were created based on major topic areas: (1) indications and contraindications, (2) dosing, (3) interactions with immunizations and medications, (4) adverse effects (potential for and management of), and (5) monitoring needs. Pertinent questions were generated and addressed by the relevant committee. The entire group participated in a modified Delphi process to establish agreement on recommendations for each question. The committee developed 46 evidence‐ and consensus‐based recommendations, each with >70% agreement among members, across all five topics. These are presented in tables and text, along with a discussion of supporting literature, and level of evidence. These evidence‐ and consensus‐based recommendations will support safe and effective use of MTX for the underserved population of pediatric patients who may benefit from this valuable, time‐honored medication.

show abstract

Section: Introductionmentioning

confidence: 99%

Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines

Siegfried

Arkin

Chiu

et al. 2023

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…As some patients had high anti-phospholipid antibodies (aPL) titers, low-dose aspirin could prevent thromboembolic events. Another limitation of thalidomide is its high cost, that affects the choice of alternative drug (77).…”

Section: Thalidomidementioning

confidence: 99%

An update on the management of refractory cutaneous lupus erythematosus

et al. 2022

View full text Add to dashboard Cite

Management of cutaneous lupus erythematosus (CLE) involves a combination of preventive measures, topical and systemic drugs, fairly similar for the different subtypes. Although guidelines exist, to date, no specific drugs have been specifically licensed for CLE. Antimalarials remain the first-line systemic treatment, but many patients do not respond, making refractory lupus a challenge for clinicians. The choice of alternative medication should be based on effectiveness, safety and cost. Most of the available drugs for CLE have been adapted from systemic lupus erythematosus (SLE) treatment but the existing literature is limited to small studies and evidence often lacks. As knowledge of pathogenesis of both CLE and SLE is improving, promising new therapies are emerging. In this review, we discuss the available medications, focusing on the novelties under development for CLE.

show abstract